Can Exercise Ameliorate Immunosenescence and Thereby Reduce Relapse in Head and Neck Cancer Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-80
SponsorChang Gung Memorial Hospital
About this trial
Through the implementation of this three-year project, investigators expect to find a safe and effective exercise prescription for patients with oral cancer after surgery. The findings will encourage and promise and add further support to the concept that exercise prescription is worth implementation as part of care for the patients with head and neck cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥20
Pathology:Squamous cell carcinoma
Need CCRT treatment
ECOG PS<2
Disqualifiers
ECOG PS≥2
Unable to tolerate basic exercise, or CCRT treatment
Mental illness or any medical illness or concurrent illness that may be aggravated by exercise training or unmanageable
Any medical condition that unsuitable for exercise
Trial design
Design model
Parallel
Treatments tested in this trial
HIIT & Record of physical activities at home.
Other interventionAfter CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times. And record of physical activities at home. According to the record set goal to acheive.
HIIT only
Other interventionAfter CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times.
Treatment groups
290 Participants
are divided into 4 treatment groupsGroup A: Head and Neck patient after CCRT treatment with HIIT training-Experimental groupExperimental treatment 2 interventions
Group B: Head and Neck patient after CCRT treatment-Experimental groupNo intervention 0 interventions
Group C: Head and Neck patient after CCRT treatment with HIIT training-Validation groupExperimental treatment 2 interventions
Group D: Head and Neck patient after CCRT treatment-Validation groupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
percent of participants with phenoage and age
To evaluate the phenoage acceleration by calculating differencehe of patients with phenoage and age.
Time frame
baseline before CCRT2
percent of participants with phenoage and age
To evaluate the phenoage acceleration by calculating differencehe of patients with phenoage and age.
Time frame
1 months after the completion of CCRT3
percent of participants with phenoage and age
To evaluate the phenoage acceleration by calculating differencehe of patients with phenoage and age.
Time frame
6 months after the completion of CCRT4
percent of participants with phenoage and age
To evaluate the phenoage acceleration by calculating differencehe of patients with phenoage and age.
Time frame
9 months after the completion of CCRTSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov